ClinicalTrials.gg
Not yet recruitingNCT06690034Updated Nov 15, 2024

Relationship of Serum Zinc Level with Severity of Diabetic Nephropathy

An observational study in Diabetic Nephropathy Type 2, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-15.

Sponsored by Assiut University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
92
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Diabetic Nephropathies by Assiut University — 16 open to participants now, 16 under way, none of them phase 3. Diabetic Nephropathies · Assiut University.

Planned enrollment
11th of 21
92 · median 92
Started
2025
with 4 others
Observational
21 of 25
14 open now
Primary completion
2026-12
later than 10 of 15 live
Registered
16th of 25
by date

Among the 25 studies in Diabetic Nephropathies by Assiut University, this one is the 11th largest by planned enrollment of the 21 observational ones that give a count, is one of 5 that started in 2025, is one of 21 observational ones, reaches primary completion later than 10 of the 15 other live ones, and was the 16th registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

16 of the 25 studies in Diabetic Nephropathies by Assiut University are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Diabetic Nephropathies by Assiut University, or all of them as a file.
02

Study summary

Zinc influences the production and action of erythropoietin (EPO), a hormone produced by the kidneys that stimulates red blood cell production.

However, further research is needed to fully understand the mechanisms and to develop evidence-based guidelines for zinc supplementation in patient with Diabetic kidney disease. this study aim to detect serum zinc level in patient with Diabetic kidney disease "CKD" and Study of association between serum zinc and serum urea, creatinine, GFR, hemoglobin ,HbA1c in DKD

Read the detailed description

Chronic kidney disease (CKD) is an irreversible , progressive disease with high morbidity and mortality that occurs commonly in the general adult population, especially in people with diabetes and hypertension . It's defined as decreased kidney function shown by glomerular filtration rate (GFR) of less than 60 mL/min per 1·73 m2, or markers of kidney damage, or both, of at least 3 months duration, regardless of the underlying cause .

Diabetic kidney disease represents the most common cause of CKD in developed countries. Approximately 30% to 40% of diabetes mellitus (DM) subjects develop Diabetic kidney disease "DKD", and its presence significantly increases the risk for morbidity and mortality.

Zinc is an essential element and is the second most abundant divalent cation in the human body (2-4 g). It is mainly distributed in skeletal muscles (57%) and bone (29%) and acts as a cofactor for more than 300 enzymes. In addition, zinc is involved in the cellular mechanisms of proliferation, maintenance of structural integrity, and in the systemic regulation of the immune system . Zinc seems to have a potential role in kidney and body homeostasis in diabetic individuals which include stabilization of insulin hexamers and pancreatic insulin storage and improved glycemic control. Decreased zinc levels can impair insulin function and glucose metabolism, potentially worsening diabetes control and increasing the risk of kidney damage. Zinc is important for maintaining endothelial cell integrity and function. Endothelial dysfunction is a hallmark of DKD, and decreased zinc levels can exacerbate vascular complications associated with diabetes. Lower serum zinc levels have been associated with increased proteinuria, a common symptom of DKD. Proteinuria indicates kidney damage and is a predictor of disease progression. Zinc is involved in modulating the immune response. Deficiency can lead to a heightened inflammatory state, exacerbating kidney damage. Several studies underline the critical role of zinc in reducing oxidative stress levels, which is considered the common denominator of the mechanisms responsible for the progression of kidney disease. Zinc is a cofactor for various enzymes involved in heme synthesis and erythropoiesis

03

Conditions studied

  • Diabetic Nephropathy Type 2

Keywords

  • serum zinc level
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with diabetic kidney disease and Diabetic patient without kidney disease as a control

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with diabetic kidney disease

Exclusion criteria

Exclusion Criteria:

  • patients on dialysis. Patient refuse to participate
  • Other renal disease "lupus nephritis,GlomeruloNephritis
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
92 participants (estimated)
Patient registry
No

Groups and cohorts

  • group 1

    Patient with Diabetic kidney disease according to KDIG

  • group 2

    patients with diabetes without chronic kidney disease

06

What researchers measure

Primary outcomes

  1. zinc level

    prevalence of hypozincemia in Diabetic kidney disease

    Time frame: baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Takao T, Yanagisawa H, Suka M, Yoshida Y, Onishi Y, Tahara T, Kikuchi T, Kushiyama A, Anai M, Takahashi K, Wakabayashi Sugawa S, Yamazaki H, Kawazu S, Iwamoto Y, Noda M, Kasuga M. Synergistic association of the copper/zinc ratio under inflammatory conditions with diabetic kidney disease in patients with type 2 diabetes: The Asahi Diabetes Complications Study. J Diabetes Investig. 2022 Feb;13(2):299-307. doi: 10.1111/jdi.13659. Epub 2021 Oct 7. PubMed 34533892 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2024
First posted
Nov 15, 2024
StartEst.
Dec 1, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Jan 1, 2027
Last update
Nov 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06690034
Lead sponsor
Assiut University
Responsible party
Salma kamal Eldin Mohamed Sayed (resident doctor at nephrology unit ,internal medicine department, Assiut University) — Principal investigator
First posted
Nov 15, 2024
Start date
Dec 1, 2025 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Nov 15, 2024

Study contacts

Salma Mohamed Sayed, resident doctors
Contact
salma.16266351@med.aun.edu.eg
+2 01060342916

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion